Novavax
Washington (AFP) - US biotech firm Novavax's Covid-19 vaccine was shown to be 100 percent protective against severe cases of the disease, including hospitalization and death, the company said Thursday following trials. But its efficacy against the South African variant fell markedly when including mild and moderate cases, results showed. The results announced Thursday were from final analyses, following interim results that were announced in late January. In a Phase 3 trial in Britain that included 15,000 participants aged 18-84, including 27 percent over the age of 65, efficacy against mild, ...
AFP
Washington (AFP) - US biotech firm Novavax said Thursday its two-shot Covid-19 vaccine showed an overall efficacy of 89.3 percent in a major Phase 3 clinical trial in Britain, and remained highly effective against a variant first identified there. But the positive news was partly offset by other results that showed it offered significantly less protection against a highly transmissible variant of the coronavirus first identified in South Africa, which is spreading rapidly around the world. Novavax said it began working on new vaccines against emerging strains in early January and expects to se...
AFP
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら